Comparative Pharmacology
Head-to-head clinical analysis: LOMUSTINE versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMUSTINE versus TREANDA.
LOMUSTINE vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibits DNA synthesis, and produces interstrand crosslinks via chloroethyl carbonium ion formation. Also has carbamoylating activity.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
130 mg/m² orally as a single dose every 6 weeks; subsequent doses adjusted based on hematologic response.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateLomustine + Digoxin
"Lomustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLomustine + Digitoxin
"Lomustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLomustine + Deslanoside
"Lomustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLomustine + Acetyldigitoxin
"Lomustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial half-life ~6 hours; terminal half-life ~16-48 hours (mean 24 hours). Metabolites have prolonged half-life up to 72 hours. Clinical context: accumulation with repeated dosing, requiring 6-week intervals.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal excretion approximately 50% (as metabolites), biliary/fecal excretion approximately 20%; remainder unaccounted, likely metabolized.
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent